Safety and Efficacy of Levetiracetam for Critically Ill Patients with Seizures

被引:0
作者
Karen M. Nau
Gavin D. Divertie
Alden K. Valentino
William D. Freeman
机构
[1] Mayo Clinic,Department of Pharmacy
[2] Mayo Clinic,Department of Critical Care
[3] Mayo Clinic,Department of Neurology
来源
Neurocritical Care | 2009年 / 11卷
关键词
Antiepileptic drugs; Intensive care units; Levetiracetam; Seizures; Status epilepticus;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:34 / 37
页数:3
相关论文
共 55 条
[1]  
Varelas PN(2006)Management of seizures in the critically ill Neurologist 12 127-39
[2]  
Spanaki M(2007)Levetiracetam: part II, the clinical profile of a novel anticonvulsant drug CNS Drug Rev 13 57-78
[3]  
De Smedt T(2007)IV levetiracetam in the management of non-convulsive status epilepticus Neurocrit Care 7 36-9
[4]  
Raedt R(2007)Levetiracetam use in critically ill patients Neurocrit Care 7 140-7
[5]  
Vonck K(2006)Use of levetiracetam in hospitalized patients Epilepsia 47 2186-8
[6]  
Boon P(2000)Pharmacokinetic profile of levetiracetam: toward ideal characteristics Pharmacol Ther 85 77-85
[7]  
Farooq MU(2005)Rapid onset of action of levetiracetam in refractory epilepsy patients Epilepsia 46 324-6
[8]  
Naravetla B(2007)The safety of levetiracetam Expert Opin Drug Saf 6 241-50
[9]  
Majid A(2006)Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study Epilepsia 47 1128-35
[10]  
Gupta R(2002)Carbamazepine toxicity during combination therapy with levetiracetam: a pharmacodynamic interaction Epilepsy Res 48 217-9